Quintiles has entered a strategic alliance with Hospital Italiano of Buenos Aires as part of the company’s Prime Site program. It will be Quintiles’ first Prime Site in Latin America. Ultimately, this agreement aims to help accelerate the collection of critical data about the safety and efficacy of investigational therapies. 
 
Prime Site and Quintiles will work together to enhance the institution’s infrastructure for conducting clinical trials in an effort to accelerate the development of new medicines and to create a more efficient clinical trial process by recruiting, enrolling and retaining more patients through the course of a trial.
 
The new Prime Site at Hospital Italiano has dedicated research facilities, full-time study coordinators, a local College of American Pathologists (CAP)-accredited lab and full-service pharmacy.
 
“According to the Tufts Center for the Study of Drug Development, timelines are typically extended to nearly double their original duration to meet desired patient enrolment levels across all therapeutic areas — delays that can increase costs, deplete resources and prolong the time it takes for drugs to get to patients in need,” said Jeanne Hecht, senior vice president of Site & Patient Networks at Quintiles. “Quintiles recognizes these challenges and is dedicated to working together differently across the healthcare system to transform drug development and achieve better patient outcomes.”
 
“Hospital Italiano is founded upon three core tenets: healthcare, education and research,” said Dr. Ventura Simonovich, Clinical Operations Coordinator at Hospital Italiano. “We believe this agreement between Hospital Italiano and Quintiles reinforces our commitment with the community of preserving lives with passion by pursuing excellence in all three areas.”